Drostanolone propionate

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Drostanolone propionate

Clinical data
Pregnancy category	X
Routes of administration	Intramuscular injection or transdermal cream
ATC code	A14
Legal status
Legal status	CA: Schedule IV US: Schedule III
Pharmacokinetic data
Bioavailability	Oral 0-2%, Intramuscular 100%
Protein binding	highly
Metabolism	hepatic
Elimination half-life	?
Excretion	renal
Identifiers
IUPAC name (2R,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2,10,13-trimethyl-1,2,4,5,6,7,8,9, 11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
CAS Number	58-19-5
PubChem CID	6011
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H36O3
Molar mass	360.53 g/mol
3D model (JSmol)	Interactive image
SMILES CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@H](C(=O)C4)C)C)C

WikiDoc Resources for Drostanolone propionate
Articles
Most recent articles on Drostanolone propionate Most cited articles on Drostanolone propionate Review articles on Drostanolone propionate Articles on Drostanolone propionate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Drostanolone propionate Images of Drostanolone propionate Photos of Drostanolone propionate Podcasts & MP3s on Drostanolone propionate Videos on Drostanolone propionate
Evidence Based Medicine
Cochrane Collaboration on Drostanolone propionate Bandolier on Drostanolone propionate TRIP on Drostanolone propionate
Clinical Trials
Ongoing Trials on Drostanolone propionate at Clinical Trials.gov Trial results on Drostanolone propionate Clinical Trials on Drostanolone propionate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Drostanolone propionate NICE Guidance on Drostanolone propionate NHS PRODIGY Guidance FDA on Drostanolone propionate CDC on Drostanolone propionate
Books
Books on Drostanolone propionate
News
Drostanolone propionate in the news Be alerted to news on Drostanolone propionate News trends on Drostanolone propionate
Commentary
Blogs on Drostanolone propionate
Definitions
Definitions of Drostanolone propionate
Patient Resources / Community
Patient resources on Drostanolone propionate Discussion groups on Drostanolone propionate Patient Handouts on Drostanolone propionate Directions to Hospitals Treating Drostanolone propionate Risk calculators and risk factors for Drostanolone propionate
Healthcare Provider Resources
Symptoms of Drostanolone propionate Causes & Risk Factors for Drostanolone propionate Diagnostic studies for Drostanolone propionate Treatment of Drostanolone propionate
Continuing Medical Education (CME)
CME Programs on Drostanolone propionate
International
Drostanolone propionate en Espanol Drostanolone propionate en Francais
Business
Drostanolone propionate in the Marketplace Patents on Drostanolone propionate
Experimental / Informatics
List of terms related to Drostanolone propionate

Drostanolone (trade name Masteron) is an anabolic/androgenic steroid. It is known to be highly androgenic and mildly anabolic. It is incapable of aromatization and has similar properties to dihydrotestosterone. It has been successfully used as a breast cancer drug but because of the high risk of virilization safer options are prescribed.

Use in sports

Masteron is used primarily by athletes who need to retain strength while losing mass. It is beneficial to runners and athletes who must remain in a certain weight class. It has gained popularity in the bodybuilding community as a diuretic and muscle defining drug.

References

• Eur J Cancer Clin Oncol. 1983 Sep;19(9):1231-7.
• Cancer Res. 1982 Nov;42(11):4408-12 Marin P, Oden B, and Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 80: 239-243, 1995
• Sem Hop. 1982 Sep 23;58(34):1919-23.

Template:WikiDoc Sources